Novartis data again demonstrate age-appropriate development when Zolgensma is used presymptomatically, and post-hoc data reveal SMA Type 1 patients could speak, swallow and maintain airway protection
Feedback and remarks of the industry and stakeholders are invited till the 25th of March 2022
Ritika has also extensively worked with clients such as WHO, GAVI Alliance, USAID, Gilead, Novartis, Sanofi Pasteur
A total of 49 projects have been approved so far for 33 critical APIs with a committed investment of Rs 3,685 crore
The award recognizes and supports promising women scientists
Amit Jaju, Senior Managing Director, India in an interview with Thomas C Thottathil outlined the steps Indian pharma companies should follow to be compliant with global regulatory requirements
It signals Cordis' renewed investment in innovation
Lynparza is approved in the US, EU, Japan and several other countries for the treatment of patients with gBRCAm, HER2-negative, metastatic breast cancer previously treated with chemotherapy based on results from the OlympiAD Phase III trial
These new chemical entities are covered by composition of matter patent applications. Financial terms of the deal were not disclosed
Tislelizumab is now approved for seven indications in China
Subscribe To Our Newsletter & Stay Updated
